NVS vs TGTX
NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases. TGTX: Commercial-stage biotech focused on anti-CD20 monoclonal antibody therapies for B-cell diseases, with FDA-approved BRIUMVI for relapsing multiple sclerosis and expanding pipeline in neurology.
Side-by-side fundamentals
| Metric | NVS | TGTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $153.08 | $52.68 | |
| Market cap as of 2026-07-23 | $229.2B | $8.3B | |
| P/E as of 2026-07-23 | 22.11 | 17.88 | TGTX lower |
| PEG as of 2026-07-23 | 3.66 | 0.02 | TGTX lower |
| Net margin as of 2026-07-23 | +22.5% | +66.0% | TGTX higher |
| Gross margin as of 2026-07-23 | +75.0% | +83.0% | TGTX higher |
| Operating margin as of 2026-07-23 | +29.9% | +20.0% | NVS higher |
| ROE as of 2026-07-23 | +29.9% | +87.4% | TGTX higher |
| ROA as of 2026-07-23 | +11.1% | +42.8% | TGTX higher |
| Debt / equity as of 2026-07-23 | 1.18 | 1.28 | NVS lower |
| Revenue growth (YoY) as of 2026-07-23 | +3.3% | +81.3% | TGTX higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +504.9% | |
| Dividend yield as of 2026-07-23 | +3.0% | n/a | |
| Beta as of 2026-07-23 | 1.17 | 1.66 | |
| 1-year return as of 2026-07-22 close | +35.8% | +41.0% | TGTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.